{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:21Z","timestamp":1792511601908,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG17536"],"award-info":[{"award-number":["IG17536"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jbo.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T11:42:31Z","timestamp":1541504551000},"page":"100205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"special_numbering":"C","title":["Metastatic bone disease: Pathogenesis and therapeutic options"],"prefix":"10.1016","volume":"15","author":[{"given":"Stella","family":"D'Oronzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2018.10.004_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2006.04.014","article-title":"Myeloma bone disease: pathogenetic mechanisms and clinical assessment","volume":"31","author":"Silvestris","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0002","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-targeted therapies in cancer-induced bone disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"321","key":"10.1016\/j.jbo.2018.10.004_bib0003","first-page":"43","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.jbo.2018.10.004_bib0004","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jbo.2018.10.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17101674","article-title":"Cancer Cell colonisation in the bone microenvironment","volume":"17","author":"Kan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2018.10.004_bib0006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"20 Suppl.","key":"10.1016\/j.jbo.2018.10.004_bib0007","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0008","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2018.10.004_bib0010","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0011","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbo.2018.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.09.001","article-title":"The role of biomarkers in the management of bone-homing malignancies","volume":"9","author":"D'Oronzo","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0014","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J. Bone Min. Res. Off. J. Am. Soc. Bone Min. Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10555-013-9420-1","article-title":"The pre-metastatic niche: finding common ground","volume":"32","author":"Sceneay","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbo.2018.10.004_bib0016","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10555-012-9379-3","article-title":"The rejuvenated scenario of epithelial\u2013mesenchymal transition (EMT) and cancer metastasis","volume":"31","author":"Meng","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbo.2018.10.004_bib0017","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2018.10.004_bib0018","first-page":"419","article-title":"Clinical significance of CXCL16\/CXCR6 expression in patients with prostate cancer","volume":"4","author":"Ha","year":"2011","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jbo.2018.10.004_bib0019","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1158\/0008-5472.CAN-12-0481","article-title":"CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis","volume":"72","author":"Lee","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0020","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.yexcr.2009.03.003","article-title":"Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor","volume":"315","author":"Saidak","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1593\/neo.91384","article-title":"GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche","volume":"12","author":"Shiozawa","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.jbo.2018.10.004_bib0022","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20110840","article-title":"Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone","volume":"208","author":"Kobayashi","year":"2011","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.jbo.2018.10.004_bib0023","article-title":"The value of biomarkers in bone metastasis","volume":"26","author":"D'Oronzo","year":"2017","journal-title":"Eur. J. Cancer Care"},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1054\/bjoc.2000.1261","article-title":"Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption","volume":"83","author":"Chiao","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.devcel.2017.05.005","article-title":"Endothelial-to-osteoblast conversion generates osteoblastic metastasis of prostate cancer","volume":"41","author":"Lin","year":"2017","journal-title":"Dev. Cell"},{"issue":"5","key":"10.1016\/j.jbo.2018.10.004_bib0026","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0027","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","article-title":"Bone marrow plasma macrophage inflammatory protein protein-1 alpha (MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics","volume":"38","author":"Wang","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0028","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ctrv.2012.03.004","article-title":"Therapeutic approaches to myeloma bone disease: an evolving story","volume":"38","author":"Longo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2018.10.004_bib0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0304-3835(83)90145-3","article-title":"Direct bone resorbing activity of murine myeloma cells","volume":"19","author":"McDonald","year":"1983","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbo.2018.10.004_bib0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1634\/theoncologist.2008-0087","article-title":"Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?","volume":"14","author":"Silvestris","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2018.10.004_bib0031","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1111\/bjh.12333","article-title":"Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation","volume":"161","author":"Tucci","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0032","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.yexcr.2017.06.023","article-title":"1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells","volume":"358","author":"Cafforio","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"15","key":"10.1016\/j.jbo.2018.10.004_bib0033","doi-asserted-by":"crossref","first-page":"25691","DOI":"10.18632\/oncotarget.14823","article-title":"The role of radiation therapy in bone metastases management","volume":"8","author":"De Felice","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jbo.2018.10.004_bib0034","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Hartsell","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jbo.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2008.05.018","article-title":"Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30\u00a0Gy in 10 fractions compared with 8\u00a0Gy in single fraction","volume":"89","author":"Foro Arnalot","year":"2008","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2018.10.004_bib0036","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0167-8140(99)00110-3","article-title":"The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study","volume":"52","author":"Steenland","year":"1999","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-005-0478-9","article-title":"Surgical treatment of bone metastasis: indications and outcomes","volume":"10","author":"Manabe","year":"2005","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0038","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13046-017-0578-1","article-title":"Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials","volume":"36","author":"Gdowski","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0039","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.jbo.2018.10.004_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbo.2018.10.004_bib0041","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00262-010-0887-0","article-title":"Aminobisphosphonate-pretreated dendritic cells trigger successful Vc9Vd2 T cell amplification for immunotherapy in advanced cancer patients","volume":"59","author":"Cabillic","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jbo.2018.10.004_bib0042","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00018-013-1495-x","article-title":"Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood cd T cells","volume":"71","author":"Kalyan","year":"2014","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.jbo.2018.10.004_bib0043","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","article-title":"Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid","volume":"1820","author":"Dedes","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.jbo.2018.10.004_bib0044","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3727\/096504010X12671222663638","article-title":"Zoledronate stimulates gamma delta T cells in prostate cancer patients","volume":"18","author":"Naoe","year":"2010","journal-title":"Oncol. Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13058-017-0815-8","article-title":"Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells","volume":"19","author":"Ubellacker","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"Suppl 3:iii","key":"10.1016\/j.jbo.2018.10.004_bib0046","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0047","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jbo.2018.10.004_bib0048","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.jbo.2018.10.004_bib0049","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0051","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0052","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with advanced prostate cancer and bone metastasis","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0053","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2013.05.001","article-title":"A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer","volume":"2","author":"Hutton","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2018.10.004_bib0054","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagy","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jbo.2018.10.004_bib0056","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2018.10.004_bib0057","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0058","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0059","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0061","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2018.10.004_bib0062","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0063","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial","volume":"26","author":"Bone","year":"2015","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jbo.2018.10.004_bib0064","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jbo.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy","volume":"318","author":"Rucci","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jbo.2018.10.004_bib0066","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of PDGFR beta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib","volume":"112","author":"Coluccia","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.10.004_bib0067","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdr261","article-title":"Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy","volume":"23","author":"Campone","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0068","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0069","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/1078-0432.CCR-15-2845","article-title":"TBCRC-010: phase I\/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis","volume":"22","author":"Mitri","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.jbo.2018.10.004_bib0071","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-016-3911-z","article-title":"Phase II studies of two different schedules of dasatinib in bone-metastasis predominant metastatic breast cancer: SWOG S0622","volume":"159","author":"Schott","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2018.10.004_bib0072","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916643725","article-title":"Effects of Src-kinase inhibition in cancer-induced bone pain","volume":"12","author":"De Felice","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.jbo.2018.10.004_bib0073","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2011.09.026","article-title":"Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases","volume":"314","author":"Hussein","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbo.2018.10.004_bib0074","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neo.2015.01.005","article-title":"Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2","volume":"17","author":"Hortobagyi","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.jbo.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0076","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jbo.2018.10.004_bib0077","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","article-title":"Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2","volume":"105","author":"Gnant","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2018.10.004_bib0078","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/abbs\/gmu069","article-title":"Everolimus and zoledronic acid-a potential synergistic treatment for lung adenocarcinoma bone metastasis","volume":"46","author":"Yu","year":"2014","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.jbo.2018.10.004_bib0079","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0080","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.urology.2015.08.008","article-title":"Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer clinical trial consortium study","volume":"86","author":"Vaishampayan","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2018.10.004_bib0081","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2014.116269","article-title":"Activity of everolimus (RAD001) in relapsed and\/or refractory multiple myeloma: a phase I study","volume":"100","author":"G\u00fcnther","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jbo.2018.10.004_bib0082","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjh.12909","article-title":"Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide","volume":"166","author":"Yee","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0083","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling","author":"Accardi","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jbo.2018.10.004_bib0084","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jbo.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14637","article-title":"Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study","volume":"178","author":"Sezer","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0086","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0087","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease","volume":"20","author":"Garcia-Gomez","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jbo.2018.10.004_bib0088","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.10.004_bib0089","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.10.004_bib0090","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jbo.2018.10.004_bib0091","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0092","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.critrevonc.2017.09.008","article-title":"The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials","volume":"120","author":"Rizzo","year":"2017","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"issue":"14","key":"10.1016\/j.jbo.2018.10.004_bib0093","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.18632\/oncotarget.3724","article-title":"Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment","volume":"6","author":"Iuliani","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jbo.2018.10.004_bib0094","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.jbo.2018.10.004_bib0095","doi-asserted-by":"crossref","first-page":"e15233","DOI":"10.1371\/journal.pone.0015233","article-title":"Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone","volume":"5","author":"Pennisi","year":"2010","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.jbo.2018.10.004_bib0096","doi-asserted-by":"crossref","first-page":"e90874","DOI":"10.1172\/jci.insight.90874","article-title":"Prevention of breast cancer skeletal metastases with parathyroid hormone","volume":"2","author":"Swami","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbo.2018.10.004_bib0097","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/804182","article-title":"Serum parathyroid hormone is a new potential risk factor in multiple myeloma","volume":"2014","author":"Kang","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.jbo.2018.10.004_bib0098","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0099","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbo.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0101","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2018.10.004_bib0102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jbo.2018.10.004_bib0103","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.10.004_bib0104","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0105","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.10.004_bib0106","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","article-title":"Increased Dickkopf-1expression in breast cancer bone metastases","volume":"97","author":"Voorzanger-Rousselot","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0107","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose determination study of BHQ880 in combination with antimyeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Ier","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V120.21.331.331","article-title":"Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression","volume":"120","author":"Munshi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jbo.2018.10.004_bib0111","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2018.10.004_bib0112","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin. Exp. Metastasis"},{"issue":"7","key":"10.1016\/j.jbo.2018.10.004_bib0113","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1359\/jbmr.090219","article-title":"Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer","volume":"24","author":"Kang","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.jbo.2018.10.004_bib0114","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.jbo.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0116","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.10.004_bib0117","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2018.10.004_bib0118","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0119","first-page":"3465","article-title":"Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis","volume":"8","author":"Qiao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.jbo.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"10921","DOI":"10.1158\/0008-5472.CAN-05-1809","article-title":"Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity","volume":"65","author":"Kitagawa","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2018.10.004_bib0121","doi-asserted-by":"crossref","first-page":"e78881","DOI":"10.1371\/journal.pone.0078881","article-title":"Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbo.2018.10.004_bib0122","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2018.10.004_bib0123","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2018.10.004_bib0124","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140752","article-title":"(223)Ra and other bone-targeting radiopharmaceuticals-the translation of radiation biology into clinical practice","volume":"88","author":"Turner","year":"2015","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0126","article-title":"Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial","author":"Parker","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0127","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"10001","key":"10.1016\/j.jbo.2018.10.004_bib0128","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jbo.2018.10.004_bib0129","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care ontario and american society of clinical oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4 Suppl","key":"10.1016\/j.jbo.2018.10.004_bib0131","article-title":"The impact of adjuvant denosumab on disease-free survival: results form 3,425 postmenopausal patients of the ABCSG-18 trial","volume":"76","author":"Gnant","year":"2016","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.jbo.2018.10.004_bib0132","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2018.36.15_suppl.501","article-title":"Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study","volume":"36","author":"Coleman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.10.004_bib0133","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2018.10.004_bib0134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418302586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418302586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:17:15Z","timestamp":1761941835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137418302586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":134,"alternative-id":["S2212137418302586"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2018.10.004","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic bone disease: Pathogenesis and therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100205"}}